Loading...
Loading...
Santarus, Inc.
SNTS and Pharming Group NV today announced that retrospective analyses of integrated efficacy data and immuno-safety data were presented in two oral presentations at the 2011 Biennial Meeting of the World Allergy Congress in Cancun, Mexico on December 6, 2011.
The data analyzed are from placebo-controlled and open-label clinical studies conducted with the investigational drug RHUCIN® (recombinant human C1 inhibitor, or C1INH) in patients with hereditary angioedema.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in